NKTR

Announcements

Nothing here yet

Daily updates

• Nektar reported extended Phase 2b results for rezpegaldesleukin in atopic dermatitis and alopecia areata, with treatment benefits persisting six months after the 12-month dosing period. Among responding alopecia patients, 63% maintained a SALT score of ≤20 and 19% reached ≤10. ZENITH AD Phase 3 has started, with ZENITH AA Phase 3 planned for early 2027.Oct 1, 2026

FDA designations

• Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia AreataAug 4, 2025

News

• Nektar reported positive 16-week induction results from the Phase 2b REZOLVE-AD trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis, published in The LancetAug 25, 2026
• Nektar Therapeutics launches the Phase 3 ZENITH AD program evaluating rezpegaldesleukin for moderate-to-severe atopic dermatitisJul 21, 2026
• Nektar reported 52-week topline REZOLVE-AA results showing deeper responses in severe alopecia areata with rezpegaldesleukinApr 20, 2026
• REZOLVE-AA Phase 2b study of rezpegaldesleukin establishes proof-of-concept in severe alopecia areataDec 16, 2025
• Nektar presents new data from REZOLVE-AD Phase 2b study for Rezpegaldesleukin in late-breaker oral presentation at EADV 2025Sep 18, 2025